Small Fiber Neuropathy: Functional Medicine Approach

Quick answer: Neurological conditions are among the fastest-growing disease categories in developed nations — MS incidence has increased 50% over the past 20 years, Parkinson’s disease prevalence is projected to double by 2040, and peripheral neuropathy affects over 20 million Americans. Yet conventional neurology focuses almost entirely on symptomatic management and immunosuppression, rarely addressing the modifiable biological factors that drive neuroinflammation, mitochondrial dysfunction, and neurodegenerative progression. Functional neurology uses an integrative framework to address the upstream drivers: gut-brain axis dysbiosis, mitochondrial impairment, oxidative stress, neuroinflammation, heavy metal neurotoxicity, vitamin and mineral deficiencies, and vascular factors — often alongside conventional disease-modifying therapies, to slow progression and sometimes produce measurable functional improvement.

Multiple Sclerosis: Beyond Immunosuppression

Multiple sclerosis (MS) is an autoimmune demyelinating disease of the CNS affecting ~1 million Americans, with complex environmental triggers acting on genetic susceptibility (HLA-DRB1*15:01 is the primary risk allele). The functional medicine contribution to MS management addresses the extensive evidence base for modifiable factors: Vitamin D: MS prevalence increases dramatically with latitude and reduced UVB exposure; low vitamin D levels at MS onset predict more aggressive disease course (Simpson 2010, Annals of Neurology). The SOLAR RCT (Camu 2019, Therapeutic Advances in Neurological Disorders) — high-dose vitamin D3 (14,000 IU/day added to IFN-β) achieved a non-significant trend toward reduced relapse rate but significant improvement in multiple secondary endpoints. Functional target: 60–80 ng/mL 25-OH-D. EBV: Bjornevik et al. (2022, Science) — 10 million-person military cohort demonstrated that EBV infection increased MS risk 32-fold; EBV molecular mimicry with GlialCAM/MOG is now the leading mechanistic explanation. This implies that controlling EBV reactivation (through immune optimization, HHV reactivation treatment in select cases) may reduce MS disease activity. Gut microbiome: MS patients consistently show reduced butyrate-producing bacteria (Faecalibacterium, Lachnospiraceae) and reduced gut-barrier integrity — potentially allowing LPS translocation that drives CNS microglial activation. FMT trials in MS are ongoing.

The Wahls Protocol — developed by Dr. Terry Wahls after her own secondary progressive MS diagnosis — is the most extensively studied functional nutrition approach to MS. Wahls eliminated her need for a tilt-recline wheelchair within 9 months and completed an 18-mile bike tour using a structured diet emphasizing mitochondrial nutrients (9 cups/day vegetables — 3 cups sulfur-rich cruciferous, 3 cups colorful, 3 cups leafy greens), adequate protein, omega-3 (phospholipid-rich), and elimination of processed foods and gluten. Wahls et al. (2014, Degenerative Neurological and Neuromuscular Disease) — pilot trial documented significant fatigue reduction; a 2021 RCT (Wahls 2021, eBioMedicine) found Wahls diet achieved significantly greater fatigue reduction than Swank diet in relapsing-remitting MS over 24 weeks. Mechanistically, the Wahls Protocol provides mitochondrial substrates (CoQ10 precursors, sulfur amino acids for glutathione, B vitamins for ETC), NRF2 activators (sulforaphane from cruciferous), and anti-inflammatory omega-3 from fatty fish.

Parkinson’s Disease: The Gut-Brain Axis and Neuroinflammation

Parkinson’s disease — affecting 1 million Americans with 90,000 new diagnoses annually — is characterized by dopaminergic neuron loss in the substantia nigra, Lewy body (α-synuclein aggregate) deposition, and progressive motor dysfunction. Functional neurology has contributed several mechanistic insights: The gut-brain axis in PD: Braak’s staging hypothesis (2003) proposed that PD pathology may begin in the enteric nervous system (gut) before spreading retrograde via the vagus nerve to the brain. Epidemiological evidence: Svensson et al. (2015) found truncal vagotomy (surgical vagus nerve disconnection) reduced PD risk by 15% (full truncal) to 40% (selective). Constipation precedes PD motor symptoms by 10–20 years in most patients. PD patients show gut dysbiosis (reduced Prevotellaceae, elevated Enterobacteriaceae/Lachnospiraceae) with intestinal α-synuclein deposition predating CNS disease in some cases. Pesticide exposure (rotenone, paraquat — both mitochondrial Complex I inhibitors) is the strongest environmental PD risk factor — NIEHS studies documented 2–3× increased PD risk with agricultural pesticide exposure.

Functional PD prevention and adjunctive care: Uric acid: epidemiological data (de Lau 2005) show a 40% lower PD risk in individuals with the highest vs. lowest serum uric acid — consistent with uric acid’s potent antioxidant activity protecting dopaminergic neurons. Functional target: uric acid 5.5–6.0 mg/dL. Caffeine: prospective cohort meta-analysis (Qi 2014) found caffeine intake inversely associated with PD risk (300mg/day associated with ~28% lower risk). Exercise: vigorous exercise (running, cycling, boxing — Rock Steady Boxing program specifically for PD) activates BDNF (brain-derived neurotrophic factor), dopamine release, and neuroplasticity, shown to slow motor progression. Nicotinamide riboside (NR): Parkinson’s involves mitochondrial Complex I dysfunction and NAD+ depletion; Parkinson patients with elevated blood NAD+ have slower disease progression in observational data. NIDA-funded Phase 2 trial of NR 2000mg/day in early PD is underway. Glutathione: substantia nigra glutathione is severely depleted in PD (50% below normal); IV glutathione infusion protocols and NAC + alpha-lipoic acid precursor loading are used in functional neurology settings. Kidd 2000, Altern Med Rev — open-label pilot showed sustained motor function improvement with IV glutathione.

Peripheral Neuropathy: Root Causes Beyond Diabetic Damage

Peripheral neuropathy — affecting >20 million Americans — is conventionally attributed primarily to diabetes, but functional medicine identifies multiple additional root causes in patients with “idiopathic” neuropathy: B12 deficiency neuropathy: The most common nutritional neuropathy; metformin (used in T2D) depletes B12 in >30% of chronic users — creating a paradoxical worsening of diabetic neuropathy through B12 depletion while treating the diabetes. All patients on metformin should have annual B12 with MMA/homocysteine testing; supplement methylcobalamin. Thiamine (B1) deficiency: Not only in alcoholics — SIBO, bariatric surgery, and high-carbohydrate diets deplete thiamine (required for pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase — both ETC entry points). Benfotiamine (fat-soluble thiamine) achieves 5× higher tissue levels than thiamine HCl; 300–600mg/day has specific diabetic neuropathy evidence (Stracke 1996 — reduced neuropathy score). Heavy metal neuropathy: Lead, arsenic, thallium, and mercury all cause sensorimotor neuropathy; arsenic neuropathy is common in areas with high groundwater arsenic. Celiac/gluten neuropathy: Hadjivassiliou 2003 (Annals of Neurology) documented that gluten neuropathy (anti-gliadin IgG mediated) is the most common cause of idiopathic neuropathy, potentially representing 50%+ of “cryptogenic” cases. Strict gluten elimination (24 months) produced stabilization and improvement in most patients.

Alpha-lipoic acid (ALA): The most evidence-based supplement for diabetic peripheral neuropathy — SYDNEY trial (Ziegler 2006, Diabetes Care) — 600mg IV ALA for 3 weeks, then oral 600mg/day — significantly reduced TCSS neuropathy score and NCS measures (nerve conduction velocity). ALA is a universal antioxidant and cofactor for mitochondrial ETC complexes — mechanism directly relevant to glucose toxicity-driven oxidative stress in diabetic neuropathy. Oral ALA 600–1200mg/day (stabilized R-ALA or R-lipoic acid form for superior bioavailability). Acetyl-L-carnitine (ALC): ALCAR 1500–3000mg/day improves nerve conduction velocity, reduces pain scores, and promotes nerve fiber regeneration in diabetic neuropathy (meta-analysis: Sima 2005, Diabetes Care). Benfotiamine 300–600mg/day + pyridoxal-5-phosphate (P5P) 50mg/day + methylcobalamin 1000–5000 mcg/day forms the core nutritional neuropathy protocol. Low-level laser therapy (LLLT) / photobiomodulation: Emerging evidence for diabetic and chemotherapy-induced peripheral neuropathy through mitochondrial cytochrome c oxidase activation and nitric oxide release.

Neuroinflammation: The Common Driver Across Neurological Conditions

Neuroinflammation — mediated by microglial activation, astrocyte reactivity, and blood-brain barrier compromise — is now recognized as a core pathological mechanism across neurodegenerative and neuropsychiatric conditions including MS, Alzheimer’s, Parkinson’s, depression, autism, and chronic fatigue. Key drivers of neuroinflammation addressable through functional medicine: Gut-brain axis permeability — LPS from gram-negative bacteria crosses a compromised gut-barrier, enters circulation, crosses a compromised blood-brain barrier, and activates TLR4 on microglia, initiating neuroinflammatory signaling. Heneka et al. (2015, Nature) demonstrated that NLRP3 inflammasome activation by LPS drives microglial IL-1β production in Alzheimer’s brains. Omega-3 / resolvin pathway: DHA-derived neuroprotectin D1 (NPD1) and docosahexaenoyl lipids in the CNS are anti-neuroinflammatory — omega-3 deficiency impairs neuroinflammation resolution. LDN (low-dose naltrexone): TLR4 antagonism on microglia reduces IL-6, TNF-α, and nitric oxide production — emerging evidence across all neuroinflammatory conditions. Sulforaphane crosses the blood-brain barrier (Kim 2013, Antioxidants & Redox Signaling) and activates NRF2 in microglia, reducing neuroinflammatory gene expression. PEA (palmitoylethanolamide) activates PPAR-α on microglia and mast cells — reviewed as a neuroinflammatory modulator by Skaper 2014.

Frequently Asked Questions

Can functional medicine slow the progression of MS?

Functional medicine does not replace disease-modifying therapies (DMTs) for MS — the available DMTs (high-efficacy agents like ocrelizumab, natalizumab, alemtuzumab) have dramatically reduced relapse rates and should be optimized with an MS specialist. However, functional medicine addresses modifiable factors that influence disease activity alongside DMTs: vitamin D optimization (target 60–80 ng/mL), omega-3 (3–4g EPA+DHA/day), Wahls-type anti-inflammatory mitochondrial diet, gut microbiome restoration, aerobic and resistance exercise, sleep optimization, and stress management. The HOLISM longitudinal study (Hadgkiss 2015) — the largest observational study of lifestyle factors in MS — found that Mediterranean diet, omega-3, exercise, and vitamin D supplementation collectively predicted significantly lower relapse rates and disability progression.

What nutritional deficiencies cause neuropathy?

Multiple nutritional deficiencies cause or worsen peripheral neuropathy: B12 deficiency (axonal degeneration — very common with metformin use, veganism, PPI use, or atrophic gastritis); thiamine/B1 deficiency (metabolic neuropathy — risk with alcoholism, SIBO, or high-carbohydrate diet without supplementation); B6 toxicity >200mg/day pyridoxine (paradoxically causes sensory neuropathy — use P5P form); folate deficiency (especially combined B12+folate deficiency); copper deficiency (demyelinating neuropathy resembling B12 deficiency — serum ceruloplasmin measures); and vitamin E deficiency (rare, affects posterior column/spinocerebellar tracts). Testing: comprehensive B-vitamin panel (B1, B2, B6 as P5P, B12 with MMA/homocysteine, folate as RBC folate), serum copper + ceruloplasmin, and provoked urine heavy metals in idiopathic cases.

Is there a functional medicine approach to preventing Parkinson’s?

Yes — emerging epidemiology and mechanistic data support several preventive strategies: eliminate pesticide exposure (organophosphate and organochlorine pesticide exposure is the strongest environmental PD risk factor — choose organic produce, use protective equipment); maintain vigorous exercise throughout adulthood (the strongest neuroprotective lifestyle factor); optimize uric acid in the 5–6 mg/dL range; maintain caffeine intake (~2–3 cups/day coffee); support gut microbiome health (Prevotellaceae enrichment associated with lower PD risk; constipation as prodromal PD symptom warrants microbiome intervention); avoid neurotoxic exposures (heavy metals, solvents — TCE/trichloroethylene is among the strongest environmental PD risk factors, documented in multiple case-control and prospective studies); and optimize mitochondrial function (NAD+ precursors, CoQ10, alpha-lipoic acid — addressing the mitochondrial Complex I impairment pathway central to PD pathology).

What is the connection between gut health and the brain?

The gut-brain axis operates through four major pathways: (1) Neural — the vagus nerve provides direct bidirectional communication between the enteric nervous system and brainstem/limbic system; (2) Endocrine — gut-derived hormones (GLP-1, PYY, ghrelin) and their metabolites (SCFA propionate, butyrate) directly influence hypothalamic and cortical function; (3) Immune — gut-derived LPS, inflammatory cytokines (IL-1β, IL-6, TNF-α), and lymphocyte subsets cross the blood-brain barrier and modulate microglial tone; (4) Metabolic — the gut microbiome produces neurotransmitter precursors (95% of serotonin is gut-produced, as are GABA, acetylcholine, and histamine via gut bacteria). Disruptions in any of these pathways — from gut dysbiosis, increased permeability, or altered microbiome composition — propagate neurologically and are now implicated in depression, anxiety, autism, Parkinson’s, Alzheimer’s, and MS.

If you have MS, Parkinson’s disease, peripheral neuropathy, or other neurological symptoms and want a comprehensive functional neurology evaluation — including nutritional biomarker assessment, gut microbiome evaluation, heavy metal screening, and an evidence-based integrative protocol — call The Private Practice at (810) 206-1402. We work alongside your neurologist to address the modifiable biological factors that influence neurological disease course.

Functional Neurology: MS, Parkinson’s, Peripheral Neuropathy, and Neuroinflammation